Puma Biotechnology Secures FDA Orphan Drug Designation For Alisertib For The Treatment Of Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Puma Biotechnology has secured FDA Orphan Drug Designation for Alisertib, a treatment for small cell lung cancer. This designation provides certain benefits, including tax credits for clinical testing.
September 21, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Puma Biotechnology's Alisertib has received FDA Orphan Drug Designation, which could provide financial benefits and expedite the drug's path to market.
The FDA Orphan Drug Designation is granted to drugs that treat rare diseases, providing benefits like tax credits for clinical testing. This could expedite Alisertib's path to market and provide financial benefits to Puma Biotechnology, potentially positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100